File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Post hoc analysis of a single IV infusion of zoledronic acid versus daily oral risedronate on lumbar spine bone mineral density in different subgroups with glucocorticoid-induced osteoporosis

TitlePost hoc analysis of a single IV infusion of zoledronic acid versus daily oral risedronate on lumbar spine bone mineral density in different subgroups with glucocorticoid-induced osteoporosis
Authors
Issue Date2012
PublisherSpringer U K. The Journal's web site is located at http://www.springer.com/medicine/orthopedics/journal/198
Citation
Osteoporosis International, 2012, v. 23 n. 3, p. 1083-1090 How to Cite?
AbstractThis study summarizes the treatment effect of zoledronic acid infusion on lumbar spine bone mineral density in different subgroups with glucocorticoid-induced osteoporosis. Zoledronic acid is significantly more effective than risedronate in increasing lumbar spine (LS) bone mineral density (BMD) in both prevention and treatment of glucocorticoid-induced osteoporosis. Introduction: In patients on glucocorticoids, a single zoledronic acid infusion significantly increased BMD versus daily oral risedronate. We assessed treatment effect on LS BMD in different patient subgroups at month 12 that contributed to the risk of osteoporosis in addition to glucocorticoids. Methods: Patients randomized to a single IV infusion of zoledronic acid 5 mg or risedronate (5 mg/day) and stratified based on glucocorticoids duration [treatment (>3 months) and prevention (≤3 months) subpopulations] were subgrouped by age; gender; menopausal status in women; dose and duration of prednisone during the trial; and baseline serum 25-OH vitamin D, LS BMD T-score, creatinine clearance, and concomitant medication use. Results: At month 12, zoledronic acid significantly increased LS BMD versus risedronate in patients ≤74 years (P < 0.05) in the treatment and 65-74 years (P = 0.0008) in the prevention subpopulation. At month 12, zoledronic acid significantly increased LS BMD versus risedronate in both subpopulations irrespective of gender (all P < 0.05), cumulative prednisone dose (all P < 0.01), and postmenopausal status (all P < 0.05). In premenopausal women, in both subpopulations, zoledronic acid significantly increased total hip BMD (all P < 0.05) versus risedronate at month 12 but not LS BMD. Osteoporotic patients in the prevention (P = 0.0189) and osteopenic patients in the treatment subpopulation (P = 0.0305) showed significant LS BMD increases with zoledronic acid versus risedronate at month 12. Conclusions: This post hoc analysis suggests that zoledronic acid is significantly more effective than risedronate in increasing LS BMD in prevention and treatment of glucocorticoid-induced osteoporosis across a wide range of patients © 2011 International Osteoporosis Foundation and National Osteoporosis Foundation.
Persistent Identifierhttp://hdl.handle.net/10722/163458
ISSN
2015 Impact Factor: 3.445
2015 SCImago Journal Rankings: 1.460
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorRoux, Cen_US
dc.contributor.authorReid, DMen_US
dc.contributor.authorDevogelaer, JPen_US
dc.contributor.authorSaag, Ken_US
dc.contributor.authorLau, CSen_US
dc.contributor.authorReginster, JYen_US
dc.contributor.authorPapanastasiou, Pen_US
dc.contributor.authorBucciRechtweg, Cen_US
dc.contributor.authorSu, Gen_US
dc.contributor.authorSambrook, PNen_US
dc.date.accessioned2012-09-05T05:31:40Z-
dc.date.available2012-09-05T05:31:40Z-
dc.date.issued2012en_US
dc.identifier.citationOsteoporosis International, 2012, v. 23 n. 3, p. 1083-1090en_US
dc.identifier.issn0937-941Xen_US
dc.identifier.urihttp://hdl.handle.net/10722/163458-
dc.description.abstractThis study summarizes the treatment effect of zoledronic acid infusion on lumbar spine bone mineral density in different subgroups with glucocorticoid-induced osteoporosis. Zoledronic acid is significantly more effective than risedronate in increasing lumbar spine (LS) bone mineral density (BMD) in both prevention and treatment of glucocorticoid-induced osteoporosis. Introduction: In patients on glucocorticoids, a single zoledronic acid infusion significantly increased BMD versus daily oral risedronate. We assessed treatment effect on LS BMD in different patient subgroups at month 12 that contributed to the risk of osteoporosis in addition to glucocorticoids. Methods: Patients randomized to a single IV infusion of zoledronic acid 5 mg or risedronate (5 mg/day) and stratified based on glucocorticoids duration [treatment (>3 months) and prevention (≤3 months) subpopulations] were subgrouped by age; gender; menopausal status in women; dose and duration of prednisone during the trial; and baseline serum 25-OH vitamin D, LS BMD T-score, creatinine clearance, and concomitant medication use. Results: At month 12, zoledronic acid significantly increased LS BMD versus risedronate in patients ≤74 years (P < 0.05) in the treatment and 65-74 years (P = 0.0008) in the prevention subpopulation. At month 12, zoledronic acid significantly increased LS BMD versus risedronate in both subpopulations irrespective of gender (all P < 0.05), cumulative prednisone dose (all P < 0.01), and postmenopausal status (all P < 0.05). In premenopausal women, in both subpopulations, zoledronic acid significantly increased total hip BMD (all P < 0.05) versus risedronate at month 12 but not LS BMD. Osteoporotic patients in the prevention (P = 0.0189) and osteopenic patients in the treatment subpopulation (P = 0.0305) showed significant LS BMD increases with zoledronic acid versus risedronate at month 12. Conclusions: This post hoc analysis suggests that zoledronic acid is significantly more effective than risedronate in increasing LS BMD in prevention and treatment of glucocorticoid-induced osteoporosis across a wide range of patients © 2011 International Osteoporosis Foundation and National Osteoporosis Foundation.en_US
dc.languageengen_US
dc.publisherSpringer U K. The Journal's web site is located at http://www.springer.com/medicine/orthopedics/journal/198en_US
dc.relation.ispartofOsteoporosis Internationalen_US
dc.subject.meshAdministration, Oralen_US
dc.subject.meshAdolescenten_US
dc.subject.meshAdulten_US
dc.subject.meshAge Factorsen_US
dc.subject.meshAgeden_US
dc.subject.meshAged, 80 And Overen_US
dc.subject.meshBone Density - Drug Effectsen_US
dc.subject.meshBone Density Conservation Agents - Administration & Dosage - Therapeutic Useen_US
dc.subject.meshDiphosphonates - Administration & Dosage - Therapeutic Useen_US
dc.subject.meshDouble-Blind Methoden_US
dc.subject.meshDrug Administration Scheduleen_US
dc.subject.meshEtidronic Acid - Administration & Dosage - Analogs & Derivatives - Therapeutic Useen_US
dc.subject.meshFemaleen_US
dc.subject.meshGlucocorticoids - Administration & Dosage - Adverse Effectsen_US
dc.subject.meshHumansen_US
dc.subject.meshImidazoles - Administration & Dosage - Therapeutic Useen_US
dc.subject.meshInfusions, Intravenousen_US
dc.subject.meshLumbar Vertebrae - Physiopathologyen_US
dc.subject.meshMaleen_US
dc.subject.meshMenopause - Physiologyen_US
dc.subject.meshMiddle Ageden_US
dc.subject.meshOsteoporosis - Chemically Induced - Drug Therapy - Physiopathology - Prevention & Controlen_US
dc.subject.meshOsteoporosis, Postmenopausal - Chemically Induced - Drug Therapy - Physiopathology - Prevention & Controlen_US
dc.subject.meshPrednisone - Administration & Dosage - Adverse Effectsen_US
dc.subject.meshSex Factorsen_US
dc.subject.meshVitamin D - Analogs & Derivatives - Blooden_US
dc.subject.meshYoung Adulten_US
dc.titlePost hoc analysis of a single IV infusion of zoledronic acid versus daily oral risedronate on lumbar spine bone mineral density in different subgroups with glucocorticoid-induced osteoporosisen_US
dc.typeArticleen_US
dc.identifier.emailLau, CS:cslau@hku.hken_US
dc.identifier.authorityLau, CS=rp01348en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1007/s00198-011-1800-1en_US
dc.identifier.pmid21975559-
dc.identifier.scopuseid_2-s2.0-84857440380en_US
dc.identifier.hkuros206729-
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-84857440380&selection=ref&src=s&origin=recordpageen_US
dc.identifier.volume23en_US
dc.identifier.issue3en_US
dc.identifier.spage1083en_US
dc.identifier.epage1090en_US
dc.identifier.isiWOS:000300251200033-
dc.publisher.placeUnited Kingdomen_US
dc.identifier.scopusauthoridRoux, C=14054986200en_US
dc.identifier.scopusauthoridReid, DM=35372429900en_US
dc.identifier.scopusauthoridDevogelaer, JP=35271465400en_US
dc.identifier.scopusauthoridSaag, K=35448182000en_US
dc.identifier.scopusauthoridLau, CS=14035682100en_US
dc.identifier.scopusauthoridReginster, JY=35378176800en_US
dc.identifier.scopusauthoridPapanastasiou, P=36874895000en_US
dc.identifier.scopusauthoridBucciRechtweg, C=35274367400en_US
dc.identifier.scopusauthoridSu, G=7201359489en_US
dc.identifier.scopusauthoridSambrook, PN=7103142193en_US
dc.identifier.citeulike9885482-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats